summari earlier week met better assess
put take compani beyond overal
growth trajectori recoveri effort remain track retir
fair amount risk around suppli expect make
invest drive top-lin growth
beyond put five year plan place
focus around margin expans return cash
sharehold key takeaway follow would
anoth year transit growth would back-
end load due factor discuss chang tax
regul expect impact tax rate
rosa could meaning share re-captur previous
expect warn letter well suppli issu
notabl de-risk
anoth transit year consist
compani prior commentari note two-year
recoveri effort track good line
sight get wamg weight averag market growth
fact suppli longer barrier achiev financi
target next focu logist plan stori notabl de-
risk around warn letter product on-track
full launch leadership team place includ
hire group presid orthoped ivan torno
growth back-end load zbh result would
impact fx sell day bone cement supplier issu
launch full commerci avail key product persona
famili rosa first fx expect headwind
full year versu prior guidanc north
translat approxim increment headwind
heavili skew toward especi taper
estim
approxim base math second sell day
net neutral full year neg impact would
fulli revers typic day compani translat
sale third bone cement supplier issu continu
impact sale tune per quarter
consist compani prior comment anniversari
final full impact new product launch would
greater benefit
continu page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort non-recur item
compani data secur llc estim reuter
continu previou page
tax outlook remain unchang expect lower tax rate versu
expect abl mitig impact regulatori tax chang underli improv
current project versu guidanc
rosa could meaning share re-captur rosa tka total knee applic rosa spine
applic submit fda late octob approv anticip rosa would
begin period limit launch upon approv full launch worth note
intend rosa compet syk mako platform said could import drive
share re-captur surgeon lose custom surgeon latter abl
offer robot advertis directli patient believ factor drive
share shift surgeon switch becom surgeon said anticip rise
tide robot could allow compani benefit within respect surgeon base
unreason assum could pent-up demand custom base rosa
releas showcas orthoped robot applic aao american academi
orthoped surgeon medial meet la vega nv includ rosa tka spine
brain well walter bionic arm attach oper tabl ceo bryan hanson
note focus build ecosystem robot person persona digit
warn letter issu notabl de-risk per note present fda
accommod effort point right direct fulli address warn
letter issu third parti expert evalu progress well compani plan invit
fda come back visit facil sometim believ notabl de-risk
fda warn letter issu last six month
capit alloc strategi focu debt repay remain use cash time
target leverag less exit thereaft compani greater focu
portfolio manag return cash sharehold via dividend share buyback etc ceo bryan
hanson note goal would diversifi busi away hips/kne america
head strategi focus identifi area bias toward map
clear path leadership understand gap could fill busi
would manag margin expans note plan tuck-in throughout
especi deal plug directli distribut channel size
compani comfort place open playbook meaning
way exit
dental like divest ceo bryan hanson note dental busi
alloc addit money invest busi offer opportun turn
busi around believ market attract deliv growth mid-singl
digit posit momentum build dental busi comment impli
would like divestitur near-term instead manag deploy wait
see approach limit period
notabl orthoped market remain stabl price within typic rang
spine complet channel chang plan kick momentum nation sale
meet orlando fl focu mobi-c robot elsewher note orthoped
sale rep turnov lowest sever quarter set sport medicin extrem
trauma singl leadership set identifi area would like
doubl final put granular incent metric place drive perform across
region segment plan put five year plan place would focus around
margin expans increas drive growth key market well return sharehold
price target nc
price target base approxim cash ep estim risk thesi
includ increas invest slower procedur volum growth price pressur disrupt
integr biomet
zimmer biomet share trade discount large-cap med-tech peer group believ
discount narrow next twelv month compani benefit leadership
new commercially-driven ceo bryan hanson oper issu resolv pipelin
begin fulli appreci
warsaw indiana-bas zimmer biomet hold one world largest orthoped implant
manufactur compani global market leader billion reconstruct orthoped
implant busi hip knee implant togeth account roughli revenu
compani report sale billion
